| ID Source | ID |
|---|---|
| PubMed CID | 54676686 |
| CHEMBL ID | 197014 |
| CHEBI ID | 121378 |
| SCHEMBL ID | 6720229 |
| Synonym |
|---|
| OPREA1_030770 |
| 3-quinolinecarboxamide, n-[2-(aminosulfonyl)phenyl]-1,2-dihydro-4-hydroxy-1-(2-methylpropyl)-2-oxo- |
| 4-hydroxy-1-isobutyl-2-oxo-n-(2-sulfamoylphenyl)quinoline-3-carboxamide |
| smr000111185 |
| MLS000106809 , |
| OPREA1_249972 |
| CHEBI:121378 |
| CHEMBL197014 , |
| MLS002539841 |
| 2-hydroxy-1-(2-methylpropyl)-4-oxo-n-(2-sulfamoylphenyl)quinoline-3-carboxamide |
| HMS2435L24 |
| AB00089856-01 |
| SCHEMBL6720229 |
| 2-hydroxy-1-(2-methylpropyl)-4-oxo-n-(2-sulfamoylphenyl)-3-quinolinecarboxamide |
| cid_54676686 |
| 1-(2-methylpropyl)-2-oxidanyl-4-oxidanylidene-n-(2-sulfamoylphenyl)quinoline-3-carboxamide |
| 2-hydroxy-1-isobutyl-4-keto-n-(2-sulfamoylphenyl)quinoline-3-carboxamide |
| cid_1370032 |
| bdbm37271 |
| AKOS025143092 |
| 4-hydroxy-1-(2-methylpropyl)-2-oxo-n-(2-sulfamoylphenyl)-3-quinolinecarboxamide |
| Q27209917 |
| Class | Description |
|---|---|
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.6310 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.6228 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 26.6795 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| 67.9K protein | Vaccinia virus | Potency | 16.8037 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| IDH1 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 3.9811 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 28.1838 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 0.0398 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 7.9433 | 0.6561 | 9.4520 | 25.1189 | AID927 |
| snurportin-1 | Homo sapiens (human) | Potency | 0.0398 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 39.8107 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| geminin | Homo sapiens (human) | Potency | 18.3564 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 10.0000 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 17.7828 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 14.1254 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 3.9811 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 3.9811 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 31.6228 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 7.9433 | 1.5849 | 13.0043 | 25.1189 | AID927 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.8730 | 10.7219 | 78.4000 | AID493155 |
| hypothetical protein SA1422 | Staphylococcus aureus subsp. aureus N315 | IC50 (µMol) | 34.8850 | 1.6200 | 20.9350 | 62.7000 | AID624317; AID651709 |
| Delta-type opioid receptor | Mus musculus (house mouse) | IC50 (µMol) | 40.0000 | 0.0001 | 0.7298 | 10.0000 | AID257140 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 40.0000 | 0.0003 | 0.3887 | 7.0000 | AID257140 |
| Integrase | Human immunodeficiency virus 1 | IC50 (µMol) | 28.0000 | 0.0005 | 1.5443 | 10.0000 | AID257140; AID257141; AID394562; AID394563 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 79.2885 | 0.0600 | 8.9128 | 130.5170 | AID1902; AID1914 |
| Estrogen receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 150.0000 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
| Estrogen receptor beta | Rattus norvegicus (Norway rat) | EC50 (µMol) | 150.0000 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID257141 | Inhibition of strand transfer catalytic activity HIV1 integrase | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25 | Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. |
| AID394562 | Inhibition of HIV1 integrase 3' processing activity by PAGE | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7 | Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors. |
| AID257140 | Inhibition of 3'-processing catalytic activity HIV1 integrase | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25 | Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. |
| AID394563 | Inhibition of HIV1 integrase strand transfer activity by PAGE | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7 | Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors. |
| AID257142 | Antiviral activity in human T cell line CEM-SS infected with HIV1 | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25 | Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||